Prometheus Biosciences, Inc.
Disclaimer : Sections of this page are auto-generated by Artificial Intelligence and shall not be understood as Investment AdviceThis page was updated : N/A. Premium customers can update this page on demand.
Newsflash
N/A
Based on these articles
Business Overview
N/A
Yahoo - Business Overview
Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially ...
Flags & Key Risks
Negative profit margins
Negative EV to Ebitda
Negative Return on Equity
Insiders are selling
Clinical stage company
Negative Revenue Trend
Pre-market negative on higher volumes
News Coverage
1 month ago @InvestorPlace
Why Is Prometheus Biosciences (RXDX) Stock Up 70% Today? |
#RXDX #prometheus #biosciences #rxdx #merck #deal |
1 month ago @GlobeNewsWire
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc. |
#RXDX #novel #crohn #conditionsmerck #autoimmune #ulcerative |
No research found for |
8 days ago @DEFA14A
DEFA14A - Proxy Statements |
#RXDX #regulatory filing #proxy #statements #RXDX |
12 days ago @DEFM14A
DEFM14A - Proxy Statements |
#RXDX #regulatory filing #proxy #statements #RXDX |
Offcanvas top
Placeholder
Offcanvas left
Placeholder
Loading...
Offcanvas bottom
Some text as placeholder. In real life you can have the elements you have chosen. Like, text, images, lists,
etc.